Extract:
“This study demonstrates that residual activity of [177Lu]Lu-PSMA-617 within the TIVAP components was below 2% of the injected activity during phantom experiments. Additionally, patient SPECT performed a few hours post-injection showed no abnormal catheter uptake and no activity in the chamber exceeding blood pool background levels. These findings suggest that [177Lu]Lu-PSMA-617 administration via TIVAP appears safe and effective, supporting its use in clinical practice particularly for patients with limited peripheral venous access.”
Reference:Lombard A, Journo S, Zaragori T, Olivier P, Claudin M, Marie PY, Bros M, Bordonné M, Verger A, Veran N, Citerne Q, Imbert L, Boursier C. Experience of [177Lu]Lu-PSMA-617-administration using totally implantable venous access port: simulated experiments and clinical SPECT analyses. EJNMMI Res. 2025 Sep 26;15(1):121. doi: 10.1186/s13550-025-01316-5. PMID: 41003905; PMCID: PMC12474817.